1. FDA. Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). Postmarketed drug safety information for patients and providers, 8/28/2009 [online]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm165489.htm . Accessed 30 Jan 2014.
2. FDA. Follow-up to the March 27, 2008 communication about the ongoing safety review of montelukast (Singulair) Postmarketed drug safety information for patients and providers, 1/13/2009 [online]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients . Accessed 16 Jan 2014.
3. Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J Allergy Clin Immunol. 2008;122(4):828–9. doi: 10.1016/j.jaci.2008.07.012 .
4. Kelsay K. Assessing risk: Data from montelukast clinical trials. J Allergy Clin Immunol. 2009;124(4):697–8. doi: 10.1016/j.jaci.2009.09.001 .
5. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):699–706.e8. doi: 10.1016/j.jaci.2009.08.011 . (Erratum in: J Allergy Clin Immunol. 2010 May;125(5):1019).